Table 4:
Cytotoxicity of designed PA against HaCaT, HCEC and HEK-293 and hemolytic activity against Human red blood cells.
| IC50 (μg/mL) | HC50 (μg/mL) | |||
|---|---|---|---|---|
| PAs | HaCaTa | HCECb | HEK-293c | Human red blood cells |
| PA 2 | 21.42 | ne | >32 | 27.11 |
| PA 3 | 17.59 | ne | >32 | 8.31 |
| PA 4 | 52.0 | 28.3 | >32 | 22.3 |
| PA 5 | 35.9 | 22.5 | 20.8 | 4.9 |
| PA 8 | 40.4 | 19.3 | >32 | 8.1 |
| PA 11 | 37.1 | 18.7 | 20.3 | 16.1 |
| PA 12 | > 150 | > 150 | >32 | >32 |
| PA 13 | > 150 | 27.5 | >32 | >32 |
a
Immortalized Human Keratinocyte;
b
Immortalized Human Colonic Epithelial Cell;
c
Human embryonic kidney cells (ATCC CRL-1573).
HaCaT, HCEC cells were incubated with various PA concentration for 24 h and the cell viability was determined by MTT assay. Assays were performed in triplicate. Cytotoxicity against HEK-293 and Hemolytic Activity were performed by CO-ADD (The Community for Antimicrobial Drug Discovery), Australia.